# Bolt Biotherapeutics to Participate in Upcoming March Conferences
Canonical URL: https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-d58ae5f3
Ticker: BOLT
Company: Bolt Biotherapeutics
Source: Bolt Biotherapeutics
Published: 2026-02-24 13:00 EST
## Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

## Article Body
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

TD Cowen 46th Annual Health Care Conference Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)

Leerink Partners Global Healthcare Conference Participating in 1x1 meetings on Wednesday, March 11, 2026

About Bolt Biotherapeutics, Inc. The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 dose escalation trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company’s Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform technology and its expertise in myeloid biology. The Company is seeking to partner BDC-3042, a Dectin-2 agonist that recently completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1. For more information, please visit https://www.boltbio.com/ .

Investor Relations and Media Contact: Matthew DeYoung Argot Partners (212) 600-1902 boltbio@argotpartners.com
## Recent Company News
- 2026-05-12 20:05 EST — [Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-b-b5fec9e5) — Source: Bolt Biotherapeutics
- 2026-03-12 20:05 EST — [Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-e284d9b8) — Source: Bolt Biotherapeutics
- 2026-02-24 13:00 EST — [Bolt Biotherapeutics to Participate in Upcoming March Conferences](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-d58ae5f3) — Source: Bolt Biotherapeutics
- 2025-11-12 21:05 EST — [Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2025-financial-results-and-provides-b-237a81ff) — Source: Bolt Biotherapeutics
- 2025-10-01 20:05 EST — [Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-20-8bbaa910) — Source: Bolt Biotherapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)